11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
about
Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March, 2017, Vienna: tailored treatments for patients with early breast cancer.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.The role of neratinib in HER2-driven breast cancer.Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Breast cancer treatment-induced cardiotoxicity.Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes.Risk Factors and Preventions of Breast Cancer.Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.eGARD: Extracting associations between genomic anomalies and drug responses from text.Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016.Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients.Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer.Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer.HER2 Positive Bilateral Metachronous Primary Breast Carcinoma: A Case Report.Advances in the management of HER2-positive early breast cancer.Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab.Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.Progress in breast cancer-can we do better?Breast Cancer Immunotherapy: An Update.Early Cardiotoxicity after Adjuvant Concomitant Treatment with Radiotherapy and Trastuzumab in Patients with Breast Cancer.Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancerNovel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugsCardio-oncology: protecting the heart from curative breast cancer treatmentProgress in targeted therapy for breast cancerOverview of Breast Cancer TherapyOptimizing (neo)adjuvant treatment of HER2-positive breast cancerSynthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancersTrastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection FractionTrastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiersSignificantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trialsRelationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860
Q33606741-C28D44DB-6FD3-409D-9AC1-D99158EA9205Q38661390-BB4C76E0-0F03-4DB4-9427-0B695D99F408Q38664492-14CEAE43-F871-4F52-9FA6-CBA3150F742EQ39375196-1598D673-E851-493C-AC04-AE9DA045E2D4Q39428826-375F6DF6-B21A-4497-8E1F-C3B7030C4848Q41341541-40E68A71-A219-4616-B7C3-AC812044BDEEQ47100005-D2A0BE17-E4B3-4819-A0F7-FC58AC8AD345Q47138534-5D32C663-CF25-4229-9007-A53AD8DC3C8CQ47271155-E6E9D984-939F-4337-9D86-6AFE07254F27Q47368780-9DB1F1B0-61E7-4613-AA05-2CD763228B6CQ47372732-965DF9B3-33EF-494D-86FA-9F36AA1695D3Q48257610-9137C3FA-598D-4255-B675-44DF23DBD356Q48262294-857EDAB5-2716-4266-B335-270282356F8DQ49884411-C765A677-DAE9-4F15-9B9F-430FF2409B21Q49961375-E72E16AE-F241-4242-8CF3-1EAEE916C12FQ50047680-6D1D7990-A0A2-439B-AB9E-F2CC1A0C1417Q50084900-673793E2-9ED7-4572-A498-6257FB8C04F6Q50089357-7B3EE5BA-897C-46EB-97F9-52691148EA7AQ52578959-F47D0760-C006-464C-AAFE-DE45C1B3CFF1Q52632717-8FCF972F-C116-4A71-96A8-95EE5FFB5FA9Q52643313-06998BFB-C2B3-4C4B-90C2-903DE54E7562Q52715470-7574B705-AF7A-4B48-B009-E4F416C2DBA1Q53839396-535C79B5-D44B-46C5-AC73-FBC1B6D1E060Q55181611-D5BE2A84-6587-4CFD-83BE-AD4CBE0DEABAQ55265106-09334768-C40E-4341-8CCE-F785D49E3716Q55288231-832BE935-13C7-401A-8D58-D00D5FC66FAFQ55360303-2E4A5B90-3A13-4C42-90D9-B8346D6D6591Q55690806-DE7563C4-5CF9-4DC7-85F4-03B38FFD9C10Q57072196-350C8532-DA08-497F-8FC0-747030844CA9Q57106864-7B77CBE1-2ABD-44A3-9474-F4FFB95BEDFAQ57108766-3F21DB30-C272-4E71-8C88-AB6B95FDDB3BQ57109788-D80EE1C6-952D-444F-B5FD-5CF1978310C4Q57110718-16CF97BF-6A72-4147-B629-8F3BE87AB097Q57111046-66E053F0-DABA-415F-8D22-1B9FA5367EF9Q57464691-2D02C1A6-C829-4F2E-8FC0-F58F23167217Q58130037-383218D6-ADC6-48C9-9444-5791AF4E7A50Q58780288-BEC92E32-0286-4BB2-95BF-0F75883D51F3Q58798350-792A2A46-8B44-4402-B6DB-3EEDF6C7EEB0Q58801931-0331F165-7C5F-44B7-8BFB-0806DDE45D28
P2860
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
11 years' follow-up of trastuz ...... Rceptin Adjuvant (HERA) trial.
@en
type
label
11 years' follow-up of trastuz ...... Rceptin Adjuvant (HERA) trial.
@en
prefLabel
11 years' follow-up of trastuz ...... Rceptin Adjuvant (HERA) trial.
@en
P2093
P2860
P50
P1433
P1476
11 years' follow-up of trastuz ...... Rceptin Adjuvant (HERA) trial.
@en
P2093
Aron Goldhirsch
Brian Leyland-Jones
Christian Jackisch
David Cameron
Eleanor McFadden
Gilberto Castro
Herceptin Adjuvant (HERA) Trial Study Team
Luca Gianni
Marion Procter
P2860
P304
P356
10.1016/S0140-6736(16)32616-2
P407
P577
2017-02-17T00:00:00Z